/Companies

Dren Bio

Foster City, US · Founded 2019 · Delaware corporation · 12 known investors

Find your way into Dren Bio

Sign up to see every warm intro you have to Dren Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Dren Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

Founders & leadership

Dren Bio was founded in 2019 by Nenad Tomasevic.

NTNenad Tomasevic
Nenad TomasevicFounder

Board

IT
Ivan TrifunovichBoard director
JW
John WesleyFounder

Investors · 12

AlexandriareportedPasadena

How we know: press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$93.1M disclosed across 3 rounds · 2019–2022

▶$62.5MraisedMar 2022 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rajeev DadooDirector
  • Nenad TomasevicExecutive Officer, Director
  • Andrew N. SchiffDirector
  • Alex KolicichDirector
  • Chandra LeoDirector
  • Kenneth R LuehrsenDirector
  • Sakae AsanumaDirector
Offering amount
$80M
Amount sold
$62.5M
First sale
Mar 2022
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.5MraisedNov 2020 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alex KolicichDirector
  • Rajeev DadooDirector
  • Sakae AsanumaDirector
  • John WesleyDirector
  • Nenad TomasevicExecutive Officer, Director
Offering amount
$60M
Amount sold
$25.5M
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.1MraisedJul 2019 · 19 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Nenad TomasevicExecutive Officer, Director
  • Ivan TrifunovichDirector
  • John WesleyDirector
Offering amount
$6M
Amount sold
$5.1M
First sale
Jul 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Companies working in the same space as Dren Bio.

In the news

Frequently asked questions

What does Dren Bio do?
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
Who founded Dren Bio?
Dren Bio was founded by Nenad Tomasevic in 2019.
Who are Dren Bio's investors?
Dren Bio's investors include 8VC, Aisling Capital, HBM Healthcare Investments, HBM Partners, Jacket River Capital Partners, Mission Bay Capital, Mission Biocapital, Olive Tree Capital and 4 more.
How much funding has Dren Bio raised?
Dren Bio has disclosed $93.1M raised across 3 rounds.
Where is Dren Bio headquartered?
Dren Bio is headquartered in Foster City, US.